At the news
? NEUTRALIMPACT 5/10 EFFECT filed Jul 22, 2026 at 00:15 ET
The SEC declared effective Outlook Therapeutics' S-3 shelf registration statement on July 21, 2026. This allows the company to offer and sell securities from time to time without additional SEC review, creating potential dilution overhang but no immediate capital raise. As a pre-revenue biotech, the shelf provides flexibility for future financing.
- S-3 shelf registration declared effective on July 21, 2026
- Company can now offer securities at any time without additional SEC review
- No specific offering amount or pricing disclosed in the effectiveness notice
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access